4 completed, 1 active not recruiting, 1 terminated. 3 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Early Phase 1 | 1 | Active not recruiting 1 |
Follow CUDC-907: new trials by email Literature Review of CUDC-907 trials Research Report on CUDC-907
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fimepinostat in Treating Brain Tumors in Children and Young Adults Fimepinostat, Therapeutic Conventional Surgery - Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma | Early Phase 1 | Active not recruiting | Sabine Mueller, MD, PhD | 30 | 2019-08-07 | 2026-10-05 |
| CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer CUDC-907 - Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 7 | 2016-12-22 | 2018-12-21 |
| Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma CUDC-907 - Lymphoma, Neuroblastoma | Phase 1 | Completed | Dana-Farber Cancer Institute | 26 | 2016-10-01 | 2026-02-11 |
| Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations CUDC-907 - Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | Phase 2 | Completed | Curis, Inc. | 70 | 2016-07-01 | 2022-04-27 |
| Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors CUDC-907 - Triple-Negative Breast Cancer, High-grade Serous Ovarian Cancer | Phase 1 | Completed | Curis, Inc. | 43 | 2014-11-01 | 2019-09-03 |
| Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma fimepinostat, Rituximab, venetoclax - Lymphoma, Relapsed Lymphoma | Phase 1 | Completed | Curis, Inc. | 106 | 2012-12-01 | 2021-05-06 |
Lymphoma (2) · Astrocytoma (1) · Brain Neoplasms (1) · Diffuse Intrinsic Pontine Glioma (1) · Glioblastoma (1) · Glioma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Medulloblastoma (1) · Neuroblastoma (1) · Thyroid Carcinoma, Anaplastic (1) · Thyroid Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Curis, Inc. (3) · Dana-Farber Cancer Institute (1) · National Cancer Institute (NCI) (1) · Sabine Mueller, MD, PhD (1)
United States (6) · Spain (1) · Switzerland (1)
David S Shulman, MD (1) · Naris Nilubol, M.D. (1) · Sabine Mueller, MD, PhD (1)